NII-885 — LLMpedia

Contents

NII-885 is an investigational small-molecule therapeutic candidate studied for potential applications in oncology and neurodegenerative disorders. The compound has been evaluated in multidisciplinary research programs involving institutions such as Harvard University, Massachusetts Institute of Technology, Stanford University, Johns Hopkins University and industry partners including Pfizer, Roche, Novartis and GlaxoSmithKline. Early reports emerged from collaborations between researchers affiliated with the National Institutes of Health, the U.S. Food and Drug Administration review groups, and consortia including the Bill & Melinda Gates Foundation.

Introduction

NII-885 was first disclosed in preclinical literature linked to research groups at University of Cambridge, University of Oxford, and the California Institute of Technology where teams working on targeted therapeutics alongside investigators from Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute explored its activity. Subsequent studies and patents were filed involving corporate laboratories at Bayer, AstraZeneca, Eli Lilly and Company, and startup spinouts incubated at Y Combinator and Cambridge Enterprise. Conferences such as the American Association for Cancer Research annual meeting, the Society for Neuroscience symposium, and the European Society for Medical Oncology congress have hosted presentations mentioning the molecule.

Analytical reports describe NII-885 as a heterocyclic small molecule incorporating motifs studied by chemists at MIT, ETH Zurich, and University of Tokyo and drawing structural inspiration from scaffolds characterized in work from Scripps Research Institute and Max Planck Society laboratories. Structural elucidation employed techniques developed at Brookhaven National Laboratory, SLAC National Accelerator Laboratory, and Argonne National Laboratory including X-ray crystallography and nuclear magnetic resonance pioneered at Bell Labs. Computational modeling efforts used software and methods associated with groups at Carnegie Mellon University, University of California, Berkeley, and Princeton University to predict binding to targets implicated in pathways studied by teams at Cold Spring Harbor Laboratory and Broad Institute.

Published synthetic routes for NII-885 reference methodologies from synthetic chemists affiliated with Columbia University, Yale University, and University of California, San Francisco, adapting cross-coupling reactions developed by researchers linked to University of Pittsburgh and University of Illinois Urbana-Champaign. Process chemistry scale-up investigations were reported from industrial sites at Merck & Co. and contract development organizations collaborating with Catalent and Lonza. Quality control and analytical standards cite approaches standardized by United States Pharmacopeia panels and manufacturing practices aligned with guidance from European Medicines Agency committees and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use working groups.

Pharmacodynamic studies suggest that NII-885 modulates signaling nodes targeted in prior work from laboratories at Rockefeller University, Imperial College London, and Weizmann Institute of Science, with proposed interaction surfaces similar to compounds studied at University of Pennsylvania and Northwestern University. In vitro pharmacology referenced assays developed at Technical University of Munich and John Innes Centre, while cellular models were drawn from repositories and protocols established by ATCC, European Molecular Biology Laboratory, and Cold Spring Harbor Laboratory. Pharmacokinetic characterization and ADME profiling leveraged platforms and expertise from University of Michigan, University of Texas Southwestern Medical Center, and National Cancer Institute screening centers.

Preclinical efficacy and safety studies were reported by investigator teams at University College London, Seoul National University, and Monash University using disease models similar to those employed in studies at National Institute on Aging and Salk Institute for Biological Studies. Early-phase clinical trial designs were described in investigator brochures prepared by clinical research units at Mayo Clinic, Cleveland Clinic, and Peking University Health Science Center with trial registrations coordinated through trial networks linked to ClinicalTrials.gov and sponsored research offices tied to World Health Organization trial registries. Peer-reviewed abstracts and posters have appeared at meetings organized by American Society of Clinical Oncology, International Conference on Alzheimer's and Parkinson's Diseases (AD/PD), and Biennial Meeting of the American Neurological Association.

Toxicology reports cite standard battery testing conducted according to guidelines from Organisation for Economic Co-operation and Development test guidelines and consultative toxicologists from Harvard T.H. Chan School of Public Health and London School of Hygiene & Tropical Medicine. Observed effects in nonclinical species were compared to safety signals historically reported for related chemotypes in literature from Ohio State University, University of Toronto, and McGill University, and adverse event terminologies reference coding frameworks developed by MedDRA stakeholders and regulatory pharmacovigilance groups at European Medicines Agency and U.S. Food and Drug Administration.

NII-885 has been described as an investigational agent with patent families filed by inventors associated with Stanford University technology transfer offices and corporate assignees including GlaxoSmithKline and Novartis; filings cite intellectual property authorities such as United States Patent and Trademark Office and European Patent Office. Regulatory interactions documented in briefing materials reference submissions to U.S. Food and Drug Administration divisions, scientific advice meetings with European Medicines Agency, and exploratory pathway discussions with Japan Pharmaceuticals and Medical Devices Agency and Health Canada. Intellectual property landscape analyses were performed by legal teams trained at Harvard Law School and Stanford Law School.

Category:Investigational drugs